Under pathological conditions, for example, neurodegenerative diseases, astrocyte activation, as reflected by increased GFAP [48] and S100β [11] levels, could lead to increased production of inflammatory mediators associated with BBB disruption [10]. This evidence concerns the gene GFAP and neurodegenerative disease.